India · Delayed Price · Currency is INR Artemis Medicare Services Statistics
Total Valuation
NSE:ARTEMISMED has a market cap or net worth of INR 50.30 billion. The enterprise value is 50.93 billion.
| Market Cap | 50.30B |
| Enterprise Value | 50.93B |
Important Dates
The last earnings date was Monday, November 2, 2026.
| Earnings Date | Nov 2, 2026 |
| Ex-Dividend Date | Jul 10, 2026 |
Share Statistics
NSE:ARTEMISMED has 158.31 million shares outstanding. The number of shares has increased by 0.08% in one year.
| Current Share Class | 158.31M |
| Shares Outstanding | 158.31M |
| Shares Change (YoY) | +0.08% |
| Shares Change (QoQ) | +0.11% |
| Owned by Insiders (%) | 0.01% |
| Owned by Institutions (%) | 1.33% |
| Float | 37.15M |
Valuation Ratios
The trailing PE ratio is 43.84 and the forward PE ratio is 30.26. NSE:ARTEMISMED's PEG ratio is 0.97.
| PE Ratio | 43.84 |
| Forward PE | 30.26 |
| PS Ratio | 4.37 |
| PB Ratio | 5.05 |
| P/TBV Ratio | 5.37 |
| P/FCF Ratio | 377.51 |
| P/OCF Ratio | 30.71 |
| PEG Ratio | 0.97 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 24.63, with an EV/FCF ratio of 382.23.
| EV / Earnings | 44.40 |
| EV / Sales | 4.43 |
| EV / EBITDA | 24.63 |
| EV / EBIT | 32.44 |
| EV / FCF | 382.23 |
Financial Position
The company has a current ratio of 1.82, with a Debt / Equity ratio of 0.33.
| Current Ratio | 1.82 |
| Quick Ratio | 1.62 |
| Debt / Equity | 0.33 |
| Debt / EBITDA | 1.57 |
| Debt / FCF | 24.31 |
| Interest Coverage | 6.60 |
Financial Efficiency
Return on equity (ROE) is 12.21% and return on invested capital (ROIC) is 10.59%.
| Return on Equity (ROE) | 12.21% |
| Return on Assets (ROA) | 6.49% |
| Return on Invested Capital (ROIC) | 10.59% |
| Return on Capital Employed (ROCE) | 11.76% |
| Weighted Average Cost of Capital (WACC) | 6.37% |
| Revenue Per Employee | 5.60M |
| Profits Per Employee | 558,207 |
| Employee Count | 2,055 |
| Asset Turnover | 0.76 |
| Inventory Turnover | 61.78 |
Taxes
In the past 12 months, NSE:ARTEMISMED has paid 385.66 million in taxes.
| Income Tax | 385.66M |
| Effective Tax Rate | 25.10% |
Stock Price Statistics
The stock price has increased by +26.12% in the last 52 weeks. The beta is 0.40, so NSE:ARTEMISMED's price volatility has been lower than the market average.
| Beta (5Y) | 0.40 |
| 52-Week Price Change | +26.12% |
| 50-Day Moving Average | 319.94 |
| 200-Day Moving Average | 274.72 |
| Relative Strength Index (RSI) | 55.95 |
| Average Volume (20 Days) | 164,895 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NSE:ARTEMISMED had revenue of INR 11.50 billion and earned 1.15 billion in profits. Earnings per share was 7.25.
| Revenue | 11.50B |
| Gross Profit | 2.61B |
| Operating Income | 1.57B |
| Pretax Income | 1.54B |
| Net Income | 1.15B |
| EBITDA | 2.02B |
| EBIT | 1.57B |
| Earnings Per Share (EPS) | 7.25 |
Balance Sheet
The company has 2.67 billion in cash and 3.24 billion in debt, with a net cash position of -567.81 million or -3.59 per share.
| Cash & Cash Equivalents | 2.67B |
| Total Debt | 3.24B |
| Net Cash | -567.81M |
| Net Cash Per Share | -3.59 |
| Equity (Book Value) | 9.96B |
| Book Value Per Share | 62.50 |
| Working Capital | 2.14B |
Cash Flow
In the last 12 months, operating cash flow was 1.64 billion and capital expenditures -1.50 billion, giving a free cash flow of 133.25 million.
| Operating Cash Flow | 1.64B |
| Capital Expenditures | -1.50B |
| Depreciation & Amortization | 449.00M |
| Net Borrowing | 62.47M |
| Free Cash Flow | 133.25M |
| FCF Per Share | 0.84 |
Margins
Gross margin is 22.66%, with operating and profit margins of 13.65% and 9.98%.
| Gross Margin | 22.66% |
| Operating Margin | 13.65% |
| Pretax Margin | 13.36% |
| Profit Margin | 9.98% |
| EBITDA Margin | 17.56% |
| EBIT Margin | 13.65% |
| FCF Margin | 1.16% |
Dividends & Yields
This stock pays an annual dividend of 0.45, which amounts to a dividend yield of 0.14%.
| Dividend Per Share | 0.45 |
| Dividend Yield | 0.14% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 5.79% |
| FCF Payout Ratio | 53.46% |
| Buyback Yield | -0.08% |
| Shareholder Yield | 0.06% |
| Earnings Yield | 2.28% |
| FCF Yield | 0.26% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Analyst Forecast
The average price target for NSE:ARTEMISMED is 356.00, which is 12.04% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 356.00 |
| Price Target Difference | 12.04% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 28.50% |
| EPS Growth Forecast (3Y) | 30.01% |
Stock Splits
The last stock split was on September 23, 2021. It was a forward split with a ratio of 10.
| Last Split Date | Sep 23, 2021 |
| Split Type | Forward |
| Split Ratio | 10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |